Bahar Saberzadeh-Ardestani, Amir Ali Khosravi, Fariborz Mansour-Ghanaei, Homayoon Vahedi, Nadieh Baniasadi, Mohammadreza Seyyedmajidi, Baran Parhizkar, Ahmad Hormati, Sayed Jalalledin Naghshbandi, Somaieh Matin, Amir Abbas Hassan Zadeh, Tarang Taghvaei, Mohsen Bahrami, Mandana Rafeey, Mitra Ahadi, Hassan Vossoughinia, Hashem Muosavi, Shahsanam Gheibi, Roya-Sadat Hosseini-Hemmatabadi, Abbas Yazdanbod, Saied Matinkhah, Farshad Sheikh Esmaeili, Hafez Fakheri, Seyed Hamid Moosavy, Iradj Maleki, Siavosh Nasseri-Moghaddam, Bardia Khosravi, Fatemeh Farahmand, Mehri Najafi, Hosein Alimadadi, Masoud Malekzadeh, Amir Anushiravani, Amir Kasaeian, Sudabeh Alatab, Anahita Sadeghi, Amir Reza Radmard, Shadi Kolahdoozan, Zeynab Rajabi, Ali Reza Sima
BACKGROUND: Data on the epidemiology of inflammatory bowel disease (IBD) in the Middle East are scarce. We aimed to describe the clinical phenotype, disease course, and medication usage of IBD cases from Iran in the Middle East. METHODS: We conducted a cross-sectional study of registered IBD patients in the Iranian Registry of Crohn's and Colitis (IRCC) from 2017 until 2022. We collected information on demographic characteristics, past medical history, family history, disease extent and location, extra-intestinal manifestations, IBD medications, and activity using the IBD-control-8 questionnaire and the Manitoba IBD index, admissions history, history of colon cancer, and IBD-related surgeries...
April 1, 2024: Archives of Iranian Medicine